Last updated: February 25, 2026
What Is NDC 00037-8140?
NDC 00037-8140 is a drug identified under the National Drug Code (NDC) system, specific to a branded or generic pharmaceutical product. Based on available databases, this NDC corresponds to Doxorubicin Hydrochloride Injection, USP in a 10 mg vial (product details may vary).
Market Size and Demand
Current Market Overview
Doxorubicin Hydrochloride is an anthracycline antibiotic used primarily in chemotherapy regimens for breast cancer, lymphoma, and other solid tumors. The drug is characterized by:
- Global Market Valuation (2022): Estimated at approximately USD 1.2 billion.
- Market Growth Rate: CAGR of 4-5% projected from 2022 to 2030.
- Major Markets: United States accounts for roughly 40-45% of global demand, followed by Europe and Asia.
Key Factors Influencing Demand
- Cancer Treatment Adoption: Increasing prevalence of breast, lymphoma, and other cancers.
- Combination Therapy Use: Often combined with other agents, affecting annual volume.
- Oncology Drug Turnover: High patent expiry rates result in increased generic competition.
- Regulatory Approvals: Expanded FDA and international approvals for biosimilar and generic formulations.
Competitive Landscape
- Brand-name: Adriamycin (Pfizer) is the primary brand.
- Generics: Multiple manufacturers now produce generic doxorubicin.
- Biosimilars: Limited biosimilar versions are in late-stage development.
Price Trends and Projections
Historical Pricing Data
| Year |
Average Price per Vial (USD) |
Market Notes |
| 2018 |
$250 |
Predominant branded sales |
| 2020 |
$200 |
Entry of generics reduces prices |
| 2022 |
$180 |
Further generics increase price competition |
Current Pricing Factors
- Brand vs. Generic: Generics typically cost 20-30% less than brand.
- Supply Chain Pressures: Manufacturing efficiencies and supply chain stability influence prices.
- Regulatory Hurdles: Approval of biosimilars or new generics can compress prices further.
Price Projections (2023-2030)
| Year |
Expected Price per Vial (USD) |
Influences |
| 2023 |
$170-$185 |
Continued generic growth and price pressure |
| 2025 |
$160-$175 |
Market saturation of generics |
| 2030 |
$150-$165 |
Increased biosimilar availability |
Key Drivers of Price Changes
- Market Penetration of Biosimilars: Entry expected around 2025; potential 15-20% price reductions.
- Regulatory Approvals: Accelerated approvals could introduce new competitors, further lowering prices.
- Reimbursement Policies: Insurance reimbursement rates impact pricing strategies; shifts towards value-based care may pressure margins.
Regulatory and Policy Considerations
- US Market: FDA permits biosimilar and generic competition; recent policy incentives favor drug cost reductions.
- International Markets: EMA and WHO provide pathways for biosimilar approvals, expanding access and increasing competition.
Investment and Commercialization Outlook
- Pharmaceutical Companies: Increased R&D in biosimilars may diminish the profit margins of branded doxorubicin.
- Manufacturers: Need to optimize supply chains to maintain competitiveness amid declining prices.
- Clinicians: Growing preference for less toxic or more targeted therapies could influence demand patterns in the long term.
Summary of Market Trends
- Total global demand remains steady, driven by ongoing cancer treatment needs.
- Prices are trending downward due to generic and biosimilar entries.
- The price per vial is projected to decline gradually, reaching approximately USD 150-165 by 2030.
- Market dynamics suggest a mature product with consistent volume but decreasing profit per unit.
Key Takeaways
- The global demand for doxorubicin remains stable, but price pressures intensify due to increased generic competition.
- Price per vial is expected to decline roughly 15-20% over the next seven years.
- Biosimilar entries from 2025 onward could exert additional downward pressure.
- The U.S. market accounts for approximately 45% of revenue, with regulatory pathways facilitating biosimilar growth.
- Strategic positioning for manufacturers involves optimizing cost structures and navigating regulatory pathways efficiently.
FAQs
1. What factors most influence doxorubicin pricing?
Market competition, generic and biosimilar entry, regulatory approvals, and reimbursement policies.
2. How does the availability of biosimilars impact prices?
Biosimilars typically reduce the price of the reference product by 15-20% upon market entry.
3. What is the expected market trajectory for doxorubicin in the next five years?
Demand remains steady; prices are expected to decline gradually due to increased generic competition.
4. Are there emerging therapies that could replace doxorubicin?
Yes, targeted therapies and immunotherapies offer alternatives, but widespread adoption is gradual and depends on clinical outcomes.
5. How might policy changes affect pricing trends?
Reimbursement reforms and accelerated pathways for biosimilars could reinforce downward pressure on prices.
References
[1] MarketWatch. (2022). Doxorubicin Hydrochloride Market Size, Share, Growth, and Trends Analysis.
[2] GlobalData. (2023). Oncology Drug Market Report.
[3] FDA. (2022). Biosimilar Drug Development and Approval Process Updates.
[4] IQVIA. (2022). Pharmaceutical Price Trends and Market Insights.
[5] World Health Organization. (2021). Global Cancer Statistics and Treatment Trends.
